Apollomics Inc., a clinical-stage biopharmaceutical company, has entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. to offer and sell up to $19,000,000 of its Class A ordinary shares. The shares will be sold from time to time through Cantor, acting as a sales agent or principal. The shares are listed on the Nasdaq Capital Market under the symbol 'APLM,' and as of May 23, 2024, the closing price was $0.265 per share. The sales may be made in 'at the market offering' as defined under Rule 415(a)(4) of the Securities Act of 1933. Cantor will receive a fixed commission of 3.0% of the gross proceeds from any shares sold. The agreement also includes indemnification and contribution provisions for certain liabilities, including those under the Securities Act. The offering aims to raise capital for clinical trials, research and development, and general corporate purposes.

Apollomics Inc., a clinical-stage biopharmaceutical company, has entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. to offer and sell up to $19,000,000 of its Class A ordinary shares. The shares will be sold from time to time through Cantor, acting as a sales agent or principal. The shares are listed on the Nasdaq Capital Market under the symbol 'APLM,' and as of May 23, 2024, the closing price was $0.265 per share. The sales may be made in 'at the market offering' as defined under Rule 415(a)(4) of the Securities Act of 1933. Cantor will receive a fixed commission of 3.0% of the gross proceeds from any shares sold. The agreement also includes indemnification and contribution provisions for certain liabilities, including those under the Securities Act. The offering aims to raise capital for clinical trials, research and development, and general corporate purposes.